The team found that the tirzepatide-treated mice lost about 20 percent of their body weight, mostly from reduced fat mass. In ...

Patients prescribed drugs to help them lose weight may experience a rebound in weight gain after stopping their prescription, ...

Some health experts view GLP-1s as a promising option for PCOS, which lacks a standard treatment and affects millions of ...

More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and ...

People who take GLP-1 drugs like Ozempic can lose weight even if they face disruptions in accessing the medications, which ...

A cutting-edge mouse study reveals that tirzepatide, the dual GLP-1/GIP drug already hailed for impressive weight loss, does more than trim fat: it slashes the growth of obesity-linked breast tumors.

Health plan trustees at a Minneapolis-based construction workers union are suing a subsidiary of UnitedHealth Group for ...

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

Tonight’s Hot Topic Tuesday revisits injectable weight-loss drugs and the new discoveries coming out about the medications.

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed by CVS Caremark.

Ozempic and Zepbound are both prescription injections that are part of the GLP-1 drug class. They have different active ...

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there? Here's what to know.